Recently, Vasan et al. (3) published a study of 1.5 million blood donors in which they investigated the association between ABO blood groups and incidence of first and recurrent venous thromboembolic and arterial events. They concluded that the study added strong evidence of a consistent association between non-O blood groups and both venous thromboembolism and cardiovascular events. Taking into account that non-O blood groups confer an overall increased risk of incident, recurrent, and provoked thromboembolism, ABO blood group may have a role in thrombosis risk assessment and could potentially be added to available clinical prediction systems (3).
In the last 4 decades, several studies have investigated the importance of ABO blood group as risk factor of occurrence of arterial thrombosis. In general, a significant increase in the incidence of ischemic heart diseases and cardiovascular mortality in patients with non-O blood groups has been observed (4). One mechanism proposed to explain the association between ABO blood type and ischemic heart disease is elevated serum fibrinogen level. Elevated fibrinogen level constitutes a valuable marker in diagnosis of PVT (5).
It is a fact that patients with non-O blood group have a higher risk of developing venous and arterial thromboembolic events than members of the O blood group.
This report is the first that shows the association between the ABO blood types and occurrence of PVT.
Despite its limitations and need to occure more evidence on this topic, think that non-O blood groups can convert is in an attractive biomarker prognosis for in development of PVT.
In agreement with the authors, I suggest using ABO blood types as a new factor in the stratification of risk of thrombosis in patients with prosthetic heart valve.
Fidel Manuel Caceres-Loriga Department of Cardiology, University Central Hospital; Lubango-Angola
